ERBB2 and gastroesophageal junction adenocarcinoma: In June 2021, RC-48 received its first Biologics License Application approval in China for the treatment of patients with HER2-overexpressing (defined as IHC2+ or 3+) locally advanced or metastatic GC (including gastroesophageal junction adenocarcinoma) who have received at least two systemic chemotherapy regimens.